Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 2
2000 3
2001 3
2002 1
2003 2
2004 2
2006 1
2014 1
2015 1
2019 1
2021 2
2022 1
2023 2
2024 4
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T, MacLennan SJ, Axelsson SE, Gandaglia G, Willemse PP, Mastris K, Ransohoff JB, Devecseri Z, Abbott T, De Meulder B, Bjartell A, Asiimwe A, N'Dow J; PIONEER Consortium. Omar MI, et al. Nat Rev Urol. 2023 Aug;20(8):494-501. doi: 10.1038/s41585-023-00748-9. Epub 2023 Apr 3. Nat Rev Urol. 2023. PMID: 37012441 Review.
Real-World Treatment Patterns and Survival in People With Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States.
Raval AD, Chen G, Korn MJ, Bernthaler A, Constantinovici N, Freedland SJ. Raval AD, et al. Among authors: constantinovici n. Clin Genitourin Cancer. 2025 Oct;23(5):102386. doi: 10.1016/j.clgc.2025.102386. Epub 2025 Jun 18. Clin Genitourin Cancer. 2025. PMID: 40670254 Free article.
Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol.
Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, Vradi E, Gandaglia G, Omar MI, MacLennan S, Zong J, Farahmand B, Maclennan SJ, Devecseri Z, Asiimwe A, Collette L, Bjartell A, Ndow J, Briganti A, Van Hemelrijck M; PIONEER Consortium. Beyer K, et al. BMJ Open. 2021 Feb 11;11(2):e040531. doi: 10.1136/bmjopen-2020-040531. BMJ Open. 2021. PMID: 33574142 Free PMC article.
Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
Russell B, Beyer K, Lawlor A, Roobol MJ, Venderbos LDF, Remmers S, Briers E, MacLennan SJ, MacLennan S, Omar MI, Van Hemelrijck M; PIONEER Consortium. Russell B, et al. Eur Urol Open Sci. 2023 Dec 19;59:27-29. doi: 10.1016/j.euros.2023.11.004. eCollection 2024 Jan. Eur Urol Open Sci. 2023. PMID: 38298764 Free PMC article.
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandström P, Verholen F, Higano CS, Shore N. George DJ, et al. Among authors: constantinovici n. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):306-313. doi: 10.1038/s41391-021-00488-0. Epub 2022 Feb 21. Prostate Cancer Prostatic Dis. 2022. PMID: 35190653 Free PMC article.
32 results